Shots:

• The P-III CASPIAN trial evaluates Imfinzi + CT or Imfinzi + CT + tremelimumab vs CT alone in 805 patients with ES-SCLC in 200+ centers across 23 countries- including the US- EU- South America- Asia & Middle East
• The results showed OS benefits & sustained efficacy after a median follow-up of ≥3yrs. with a 29% reduction in risk of death; m-OS (12.9 vs 10.5mos.)- well-tolerated safety profile consistent with the known profiles of the therapy- patients experienced a serious AEs (32.5% vs 36.5%)
• In an exploratory analysis- patients were alive @3yrs. (17.6% vs 5.8%) & survival benefits were consistent across all subgroups. The therapy is also being evaluated in the P-III ADRIATIC trial for SCLC

  | Ref: Businesswire | Image: New Europe